Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock
Shares of Omeros's (NASDAQ: OMER) traded up as much as 6 percent Thursday morning after the company's announcement of an NDA submission for its intraocular lens replacement surgery treatment OMS302.
The stock charged to a session high of $6.19 (up 15 percent) heading into the last hour of the morning session following comments from Wedbush analyst Liana Moussatos.
She anticipates a 90 percent probability of the FDA accepting the filing for review by late September of this year, with 10-15 percent potential upside in this instance.
Moussatos estimates an 80 percent probability of the NDA being approved by the FDA in mid-2014 with potential upside of 20-40 percent if the approval is made.
Citing peak annual sales for OMS302 of about $479 million and potential partnerships and pipeline progress during the remainder of 2013, Moussatos reiterated an Outperform rating and $18 price target on OMER.
Latest Ratings for OMER
|Apr 2016||Roth Capital||Terminates||Buy|
|Aug 2015||Roth Capital||Initiates Coverage on||Buy|
|Feb 2014||McNicoll Lewis Vlak||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.